TY - JOUR
T1 - Vogt-Koyanagi-Harada disease
AU - Joye, Ashlin
AU - Suhler, Eric
N1 - Funding Information:
Drs. Joye and Suhler are supported by an institutional grant to the Casey Eye Institute from Research to Prevent Blindness. Dr. Suhler is supported by the Department of Veterans Affairs. Dr. Suhler has received research support and consulting fees from Abbvie, Clearside, EyeGate, EyePoint, Eyevensys and Gilead.
Publisher Copyright:
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - Purpose of reviewHere, we provide an overview of Vogt-Koyanagi-Harada disease (VKH), including recent updates in our understanding of disease pathophysiology, classification and therapeutics.Recent findingsAdvancements in bioinformatics, metabolomics and genomics investigations continue to illuminate VKH pathogenesis, and may provide insight into future therapeutic options. Multimodal imaging is indispensable in the initial evaluation of VKH, and is becoming increasingly important in understanding disease pathogenesis, as well as monitoring therapeutic response. Enhanced VKH classification criteria, released in 2021, provide standardized guidelines and terminology for clinical and research purposes.SummaryModern research and imaging techniques continue to improve our understanding of VKH; more work is needed to further elucidate pathogenic mechanisms and establish optimal therapeutic recommendations.
AB - Purpose of reviewHere, we provide an overview of Vogt-Koyanagi-Harada disease (VKH), including recent updates in our understanding of disease pathophysiology, classification and therapeutics.Recent findingsAdvancements in bioinformatics, metabolomics and genomics investigations continue to illuminate VKH pathogenesis, and may provide insight into future therapeutic options. Multimodal imaging is indispensable in the initial evaluation of VKH, and is becoming increasingly important in understanding disease pathogenesis, as well as monitoring therapeutic response. Enhanced VKH classification criteria, released in 2021, provide standardized guidelines and terminology for clinical and research purposes.SummaryModern research and imaging techniques continue to improve our understanding of VKH; more work is needed to further elucidate pathogenic mechanisms and establish optimal therapeutic recommendations.
KW - Voyt-Koyanagi-Harada
KW - autoimmune
KW - classification criteria
KW - multimodal imaging
KW - uveitis
UR - http://www.scopus.com/inward/record.url?scp=85117715334&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85117715334&partnerID=8YFLogxK
U2 - 10.1097/ICU.0000000000000809
DO - 10.1097/ICU.0000000000000809
M3 - Review article
C2 - 34545845
AN - SCOPUS:85117715334
SN - 1040-8738
VL - 32
SP - 574
EP - 582
JO - Current Opinion in Ophthalmology
JF - Current Opinion in Ophthalmology
IS - 6
ER -